7682-14-6

Basic information

• Product Name: N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID
• Synonyms: N-ALPHA-ACETYL-DL-2-AMINOBUTYRIC ACID;N-ACETYL-DL-2-AMINO-BUTYRIC ACID;N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID;2-ACETAMIDO-N-BUTYRIC ACID;AC-DL-2-ABU-OH;AC-DL-2-AMINOBUTANOIC ACID;AC-DL-ABU-OH;AC-DL-ALPHA-AMINOBUTYRIC ACID
• CAS NO: 7682-14-6
• Molecular Formula: C6H11NO3
• Molecular Weight: 145.16
• Mol File: 7682-14-6.mol

Chemical Properties

• Boiling Point: 368.2 ºCat 760 mmHg
• Flash Point: 176.5 ºC
• Appearance: /
• Density: 1.129 g/cm³
• Vapor Pressure: 1.97E-06mmHg at 25°C
• Refractive Index: 1.456
• CAS DataBase Reference: N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID(7682-14-6)
• EPA Substance Registry System: N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID(7682-14-6)

Safety Data

• Hazardous Substances Data: 7682-14-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID is used as a key intermediate in the production of certain drugs, contributing to the development of novel therapeutic agents.
Used in Research as a Biochemical Tool:
As a biochemical tool, N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID aids researchers in studying various biological processes and mechanisms, furthering scientific understanding in the field.
Used in the Synthesis of Peptides and Organic Compounds:
N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID is utilized in the synthesis of peptides and other organic compounds, expanding the scope of chemical and pharmaceutical applications.
Used in Neurological Disorder Treatment:
N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID is used as a potential therapeutic agent for the treatment of neurological disorders, leveraging its neuroprotective properties to mitigate disease progression.
Used in Cognitive Decline Intervention:
With its cognitive enhancing capabilities, N-ACETYL-DL-2-AMINO-N-BUTYRIC ACID is employed in interventions aimed at addressing cognitive decline, offering support for maintaining cognitive health.

InChI:InChI=1/C6H11NO3/c1-3-5(6(9)10)7-4(2)8/h5H,3H2,1-2H3,(H,7,8)(H,9,10)

Upstream product

• 7211-57-6 2-(acetylamino)butanoic acid 
• 62973-41-5 2-(N-Acetylamino-)-buttersaeureethylester 
• 2623-91-8 (R)-2-aminobutyric acid 
• 108-24-7 acetic anhydride 
• 20306-86-9 (S)-N-(1-phenylpropyl)acetamide 
• 50285-36-4 N-(1-Ethyl-2-propinyl)acetamid 
• 1492-24-6 L-2-aminobutyric acid 
• 60-35-5 acetamide 
• 201230-82-2 carbon monoxide 
• 123-38-6 propionaldehyde 
• 2835-81-6 2-aminobutanoic acid 
• 75-56-9 methyloxirane 
• 107-18-6 allyl alcohol 
• 692-33-1 N-allylacetamide 

Downstream Products

• 66927-25-1 2-Acetylamino-N,N-diphenyl-butyramide 
• 66927-32-0 (4-ethyl-2-methyl-oxazol-5-yl)-diphenyl-amine 
• 57357-44-5 (Di-N-acetyl-α-aminobutyryloxyjod)-benzol 

Relevant articles and documents

Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres

Hepsin is a type II transmembrane serine protease (TTSP) associated with cell proliferation and overexpressed in several types of cancer including prostate cancer (PCa). Because of its significant role in cancer progression and metastasis, hepsin is an attractive protein as a potential therapeutic and diagnostic biomarker for PCa. Based on the reported Leu-Arg dipeptide-based hepsin inhibitors, we performed structural modification and determined in vitro hepsin- and matriptase-inhibitory activities. Comprehensive structure-activity relationship studies identified that the p-guanidinophenylalanine-based dipeptide analog 22a exhibited a strong hepsin-inhibitory activity (Ki = 50.5 nM) and 22-fold hepsin selectivity over matriptase. Compound 22a could be a prototype molecule for structural optimization of dipeptide-based hepsin inhibitors.

Amidoearbonylation of aldehydes utilizing cobalt oxide-supported gold nanoparticles as a heterogeneous catalyst

Cobalt oxide-supported gold-nanoparticles-catalyzed transformation of aldehydes and their equivalents to N-acyl-α-arnino acids was achieved. The desired products were obtained in moderate to excellent yields under milder reaction conditions than previous reports employing octacarbonyldicobalt as a catalyst. Copyright

Application of aminoacylase I to the enantioselective resolution of α-amino acid esters and amides

Aminoacylase I from Aspergillus melleus, a readily available and inexpensive enzyme mainly used in the industrial production of enantiopure L-amino acids from their N-acetyl derivatives, is shown to hydrolyze the esters and amides of natural and non-natural amino acids with high enantioselectivity (for the ester hydrolysis, E is up to 76, in case of amides E >300). The reaction rates of amide and ester hydrolysis are comparable, and in some cases these conversions proceeded even faster than 'traditional' aminoacylase- catalyzed hydrolysis of N-acetyl derivatives thus providing new possibilities for the resolution of the corresponding racemates. This novel approach provides an alternative route for the biocatalytic production of optically active amino acids and their derivatives.

Novel heterocycles 3

The invention relates to 7-(4-tert butyl-cyclohexyl)-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Synthesis of N-Acetyl-α-aminobutyric Acid via Amidocarbonylation: A Case Study

The synthesis of N-acetyl-α-aminobutyric acid by amidocarbonylation of propionaldehyde with acetamide in the presence of palladium catalysts is studied in detail. The influence of various reaction conditions and compositions (e.g., the co-catalysts acid and bromide) on the yield of N-acetyl-α-aminobutyric acid is shown. For the first time it is demonstrated that the palladium-catalyzed amidocarbonylations of aldehydes can be run with significantly lower halide concentrations (a major yield decrease. While phosphine-free catalyst systems give best yields at low CO pressure, phosphine-ligated palladium catalysts lead to better yields at higher CO pressure. At low palladium loadings (0.1 mol %), unwanted condensation reactions of propionaldehyde become increasingly competitive.

7-AMINOIMIDAZOTRIAZONES

The invention relates to novel 7-amino-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

5-ETHYL-IMIDAZO (5,1-F) (1,2,4,) TRIAZIN-4 (3H) -ONES AS PHOSPHODIESTERASE INHIBITORS

The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

5-ETHYLIMIDAROTRIAZONES

The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Substituted imidazotriazinones

The present invention relates to new substituted imidazotriazinones, processes for their preparation, and their use for the production of medicaments, in particular for improving perception, concentration power, learning power and/or memory power.

L-Methionine related 1-amino acids by acylase cleavage of their corresponding N-acetyl-DL-derivatives

Acylase I from Aspergillus oryzae is an even more useful enzyme than suggested so far. Besides standard amino acids such as L-Met, L-Val and L-Phe, a number of additional sulfur- and selenium-containing amino acids can be obtained at useful reaction rates and in very high enantiomeric purity by kinetic resolution of the respective N-acetyl-DL-amino acids.